Inside The New Era of Longevity Supplements
More and more people are investing their time and energy into longevity — it's not just living longer, but living happier, healthier and staying productive well past what has been considered "old age." McKinsey reports that up to 60 percent of consumers across health and wellness markets say that healthy aging is a "top" or "very important" priority. The movement has created a boost in the health and wellness businesses, and to get an overview of the longevity supplements space, we spoke with Dr. Luke Winegard, the Chief Operating Officer at Longevity Method.
Entrepreneur: What is driving the current boom in the longevity supplement market?
Dr. Luke Winegard: Growing consumer demand for health and wellness products is creating explosive growth in the longevity supplement market. Scientific advancements and increasing health consciousness are driving this trend, with consumers now focused on "healthspan" — not just how long they live, but how well they live. The pursuit of longevity has moved from being a niche interest of visionaries to becoming mainstream in 2025.
What does "healthspan" mean and why is it important?
Healthspan refers to the period of life spent in good health, free from chronic diseases and disabilities. Today's consumers are concerned not just about adding years to their lives, but making those years healthy, productive, and vital. This represents a cultural shift toward proactive self-optimization where maintaining energy, cognitive sharpness, and resilience is just as important as achieving physical goals.
How popular has longevity become in mainstream culture?
The cultural conversation around longevity has exploded online. Searches for "longevity supplements," "biohacking," and "healthspan" have seen notable growth across major platforms like YouTube and TikTok. Related hashtags such as #Longevity and #Biohacking consistently trend and reach millions of engaged viewers, indicating that living longer and better is now a major lifestyle focus driving global wellness trends.
Related: My Relentless Ambition Cost Me My Health. Here's How to Avoid Making My Mistakes.
What are the key longevity compounds and how do they work?
Several compounds are at the forefront of longevity supplementation. They include:
NMN (Nicotinamide Mononucleotide): Helps maintain cellular energy by increasing levels of NAD+, a coenzyme necessary for mitochondrial function. Research by Dr. David Sinclair at Harvard Medical School showed that restoring NAD+ levels in aged mice could reverse aging markers, increase DNA repair, and enhance endurance.
Resveratrol: A polyphenol found in red wine that activates sirtuins proteins involved in cellular repair and metabolic health, especially when taken with NAD+ boosters.
Fisetin and Quercetin: Natural flavonoids that act as senolytics, clearing senescent "zombie" cells that have stopped dividing but haven't died, which can accumulate with age and cause chronic inflammation.
Spermidine: A polyamine that stimulates autophagy — the body's internal "self-clean-up" process of damaged proteins and cellular debris.
What evidence supports the effectiveness of these compounds?
Research has demonstrated promising results for several compounds. Harvard Medical School studies on NMN showed reversal of aging markers in mice. A recent randomized controlled trial published in Nature Communications found that spermidine supplementation improved cardiovascular markers and cognitive function in older adults, suggesting its usefulness in integrated longevity strategies.
What approach are leading brands taking to longevity supplementation?
Forward-thinking brands are taking a whole-system approach to supplement design, recognizing that aging is a complex biological process. Companies like Longevity Method offer formulations that go beyond single-compound solutions, combining clinically validated ingredients that support mitochondrial health, cellular renewal, cognitive function, sleep quality, and hormonal balance. This philosophy treats lifespan and healthspan as interdependent goals requiring precision, synergy, and deep understanding of aging science. We use the best ingredients, at maximum potency and in the right (clinically tested) dosages, while manufacturing according to the highest standards of safety and quality (FSSC 22000 and GMP) in both the US for the North American market, and the Netherlands, from where we serve our European clients.
Related: Even the Strongest Leaders Burn Out — Here's the Best Way to Shake the Fatigue
What does the market outlook look like for longevity supplements?
The market trajectory shows longevity science becoming one of the most dynamic frontiers in the $1.8 trillion wellness industry. McKinsey's 2024 report identifies longevity, personalized nutrition, and preventive health as key areas of consumer-driven growth. There are significant commercial opportunities in product development, personalized health technologies, diagnostics, and beyond.
What are consumers expecting from longevity products today?
Consumer attitudes and behaviors are changing significantly. People want greater control over their health and expect companies to provide effective, science-backed solutions. Clinically proven products are now prioritized over those with purely natural or "clean" claims. Consumers also demand more transparency regarding sourcing, formulation, and efficacy, and they want to start their wellness journeys immediately rather than waiting.
Related: How to Set Boundaries and Protect Your Peace When You're Overwhelmed
What areas beyond traditional supplementation are becoming important for longevity?
Sleep support, gut health, metabolic optimization, and cognitive resilience are no longer niche topics — they're cornerstones of a modern, longevity-focused lifestyle. The focus has expanded beyond just extending lifespan to encompass energy, cognition, vitality, emotional resilience, and metabolic health as essential components of healthspan.
What's the key message for entrepreneurs and investors interested in this space?
The message is clear and simple: stay focused. Longevity is a rapidly expanding market, not an abstract scientific pursuit. Brands that understand healthspan and see supplements as tools for human optimization are setting new industry standards. The era of living longer and living better isn't coming in the future — it's already here, presenting immediate opportunities for those ready to embrace this revolution.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
13 minutes ago
- Associated Press
Oberon, a Division of Chatsworth Products (CPI), to Showcase Cisco-Specific Wireless Mounting Solutions at Cisco Live 2025
SIMI VALLEY, Calif., June 5, 2025 /PRNewswire/ -- Oberon, a Cisco Select Developer Partner, will highlight its latest wireless access point enclosures and mounting solutions designed specifically for Cisco Wireless Access Points, at Cisco Live! 2025 taking place June 8-12 in San Diego. At Cisco Live! Oberon will be showing suspended ceiling, hard ceiling, open ceiling, and wall mounting solutions; as well as public venue, industrial, warehouse, and outdoor enclosure and mounting solutions for the new CW9176I, CW9178I and other Cisco access points. Oberon is the leader in secure and aesthetic mounting solutions for wireless access points. Oberon products have helped thousands of end users, network designers, integrators, and managed service providers seamlessly integrate wireless infrastructure into any venue. Oberon products are used where physical security, network availability, and wireless coverage are paramount. 'We are committed to helping customers integrate wireless networks into any venue with the desired physical security, performance, aesthetic elements, and serviceability,' said Jeff O'Bryan, director, Strategic Partnerships, Oberon. 'Our Cisco-specific solutions provide a clear pathway for supporting current and future generations of Cisco Wireless access points, including Wi-Fi 7.' Visit Chatsworth Products and Oberon in Booth #2843 at Cisco Live 2025 to see firsthand how Oberon simplifies wireless deployments and supports next-generation connectivity. For more information, visit About Oberon Oberon, a division of Chatsworth Products (CPI), is a leading designer and manufacturer of enclosures and mounting solutions for wireless access points, antennas, and other networking equipment. Trusted by thousands of organizations worldwide, Oberon solutions help ensure optimal wireless performance while preserving the integrity and aesthetics of the environment. Contact Maren Price Chatsworth Products 612-387-5115 [email protected] View original content to download multimedia: SOURCE Chatsworth Products, Inc.
News24
27 minutes ago
- News24
Joshua Jackson in custody battle with his ex-wife over daughter's schooling
The ink has barely dried on Joshua Jackson and Jodie Turner-Smith's divorce papers, and already the exes are locked in a bitter legal dispute over their shared parenting arrangement. The Doctor Odyssey star has filed an emergency custody review, claiming his ex-wife enrolled their five-year-old daughter, Juno, in a new school without his consent. In the documents, obtained by People magazine, Joshua (46) alleges that Jodie (38) believes, 'it's no big deal to force Juno to start over with a new school'. He also complains that the new school is 45 minutes away from his home, making regular drop-offs and pick-ups nearly impossible for him. However, Joshua's concern goes beyond the school change itself. 'Jodie is attempting to create a scenario where Juno travels with her rather than attending a traditional school,' he claims. The Dawson's Creek star wants the court to order that their daughter remains in her current school in Calabasas, in Los Angeles, for the upcoming academic year. He also wants it stipulated that both parents must agree before any future school changes can be made. View this post on Instagram A post shared by THE AGENCY: CENTRAL INTELLIGENCE (@theagency_sho) Joshua and Jodie met at a 2018 party hosted by R&B singer Usher. They married in secret a year later before welcoming Juno in April 2020. In October 2023, the British model and actress filed for divorce on the grounds of 'irreconcilable differences'. Joshua recently told USA Today that he believes Jodie is attempting to change their daughter's schooling so there is more flexibility for Juno to accompany her when she needs to travel for work. READ MORE| 'I don't think of it as a failure' – Jodie Turner-Smith on divorcing Joshua Jackson He says he thinks maintaining educational stability is important for their daughter's well-being during her formative years – something he didn't experience as a child actor. 'I started acting at a young age. I have spent a lot of time with on-set or on-location tutors,' he said. 'Even in the best case, it cannot begin to provide a child with the same nurturing and enrichment, peer relationships and social skills that a classroom and school community environment provides.' He added that Juno has already endured a lot of changes, from their divorce to her home burning down during the LA wildfires in January, so she doesn't need any more turmoil. 'Unnecessary school change cannot be in her interests.' Jodie is yet to speak publicly on the matter. Despite their legal woes, it seems they're both moving on with their lives. View this post on Instagram A post shared by Joshua Jackson (@vancityjax) Jodie currently stars in The Agency as Dr Sami Zahir, an academic who becomes romantically involved with an undercover CIA agent. Describing her role she says, 'I love playing a dark-skinned Sudanese woman speaking Arabic on this show. I believe it's one of the most beautiful languages on this planet and I hope that Arabic-speaking people feel represented.' She is also set to be filming in London throughout next year. Meanwhile, Joshua is gearing up to return to his home in LA, which had to be rebuilt after being destroyed in the wildfires.
Yahoo
37 minutes ago
- Yahoo
2 Recession-Proof Stocks to Buy and Hold
Even amid an uncertain economic environment, reliable companies can be found. Zoetis helps people care for pets, which many consider as honorary family members. HCA Healthcare offers services in high demand, regardless of economic conditions. 10 stocks we like better than Zoetis › President Trump's trade policies are sparking concerns about a potential recession. Though it's hard to predict an upcoming economic downturn, it's never a bad idea for investors to buy shares of companies that can perform relatively well even in bad times. These corporations often have robust underlying businesses built to deliver consistent results and superior returns over the long run. Here are two great examples for investors to consider: Zoetis (NYSE: ZTS) and HCA Healthcare (NYSE: HCA). Zoetis, a leading animal health company, has faced some challenges over the past year. The company's recent financial results weren't great, and it is dealing with increased competition for some of its growth drivers, including Apoquel, a medicine to treat allergic itch in dogs. However, as Zoetis points out, there is significant whitespace in this niche. It estimates that 13 million dogs are eligible for the medicine but aren't on any prescription, and another 7 million are undertreated. The company currently treats 12 million dogs with Apoquel and Cytopoint, a similar medicine. Although Zoetis markets products for livestock, poultry, and other animals, the company's work with pets, particularly cats and dogs, is one of the primary reasons it can survive a recession relatively unscathed. People view their pets as family members and are more than willing to pay a significant amount to ensure they are well cared for. The increased humanization of pets should also be a significant long-term growth driver for Zoetis, a trend that is particularly prevalent among younger generations, who are less likely to have children than older ones. It might be pushing it to say that pets are the new kids, but it's not too far from the truth for many pet owners. The rest of Zoetis' business grants it significant diversity. The animal health leader generally grows its revenue at rates faster than the industry average, something it has been able to do for a while, despite competition, through the continuous development of newer medicines. Two of its more recent important approvals, Solensia and Librela that treat osteoarthritis pain in cats and dogs, respectively, are becoming key growth drivers, too. So, despite being slightly in the red over the trailing-12-month period, Zoetis is well-equipped to handle a recession if one is coming, while delivering strong returns in the long run. Lastly, the stock is also an excellent pick for income seekers despite its unimpressive forward yield of 1.2%. Zoetis has increased its payouts by 502% in the past decade. Whether it's for dividends or growth, the healthcare specialist is a great option. HCA Healthcare's business remains in high demand even in recessions. The company is a leading hospital chain in the U.S., and even during economic downturns, people still require critical medical care. True, some procedures performed in the company's facilities are optional. Even for those that aren't, patients may sometimes postpone them when things get tough. So, there will be an impact on the company's results, but it should be fairly minimal. Over the past year, the company has faced another source of headwinds. Various natural disasters, including hurricanes, impacted its financial results in some areas, resulting in lower revenue than anticipated. Still, HCA Healthcare continues to deliver decent updates. In the first quarter, the company's revenue increased by a modest 5.7% year over year to $18.3 billion. Its earnings per share came in at $6.45, up 8.8% compared to the year-ago period. Despite this headwind, HCA Healthcare's long-term prospects are attractive. An aging population that will require more medical care should lead to increased spending on precisely the kinds of services it offers. HCA Healthcare has also deepened its relationships with physicians, patients, and third-party payers over time, partly through the adoption of more services. It would be challenging for any newcomer to seriously challenge HCA Healthcare, considering the ecosystem it has already built, which arguably grants it a network effect. Although there is competition, HCA Healthcare has generally increased its market share over the past decade. The stock should continue delivering superior returns long after the next recession hits, whenever that happens. Before you buy stock in Zoetis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Zoetis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Zoetis. The Motley Fool recommends HCA Healthcare. The Motley Fool has a disclosure policy. 2 Recession-Proof Stocks to Buy and Hold was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
